• Quick Order
  • Careers
  • Support
Therapeutic antibody blocking PD-1

Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting

George R. Brown Convention Center, Houston, Texas

November 06, 2024 - November 10, 2024

The SITC Annual Meeting brings together a global community of scientists focused on cancer immunotherapy and tumor immunology. ATCC will be exhibiting at the event to showcase our solutions for oncology and immuno-oncology. Join us at booth #823 to explore our immune checkpoint reporter cells, CAR-T luciferase reporter cells, THP-1 reporter cells, 2-D and 3-D patient-derived cancer models, human primary cells, cancer panels, and more!

Want to speak to one of ATCC’s representatives about a product or service? Contact us so we can discuss your needs.

Contact us

Oncology and Immuno-oncology

To fight cancer, scientists need access to a wide variety of model systems to elucidate the mechanisms behind the growth and metastasis of each tumor type. ATCC supports this critical need by providing a comprehensive portfolio of authenticated cell lines, advanced biological models, cancer panels, and patient-derived models that can be used in biomarker discovery, tumor biology studies, drug screening, immuno-oncology, and more. Explore our resources below to see how we can support your oncology and immuno-oncology studies.

Explore advanced biological models

Browse our featured resources

CAR-T cells, CAR-Target, CD19, CD20, HER2 Application note

Luciferase Reporter Cancer Cell Lines Facilitate CAR-T Development

This report describes ATCC luciferase reporter solid and liquid tumor cell lines that express tumor antigens such as CD19, CD20, and HER2. Learn how you can incorporate these target cells into your T-Cell cytotoxicity assays to enable your breakthroughs in immuno-oncology.

Immune checkpoint inhibitors: Interaction between PD-1 (blue) on a T-cell and PD-L1 (red) on a cancer cell blocked by therapeutic antibodies Application note

GAS-LUC2 Reporter Cell Lines for Immune Checkpoint Drug Screening in Solid Tumors

This study demonstrates the use of three robust, responsive, and reproducible GAS-Luc2 reporter solid tumor cell lines for the assessment of T cell and other immune/tumor microenvironmental cell-mediated immune responses triggered by PD-1/PD-L1, CD-155/TIGIT, or B7-H3 (CD276) immune checkpoints.

immune checkpoint inhibitor Brochure

Checkpoint Luciferase Reporter Cells

To facilitate large-scale drug discovery of immune checkpoint inhibitors, ATCC created tumor and immune cell lines with high endogenous expression of checkpoint inhibitory and co-stimulatory expression levels.

Fluorescent blue and green spheres of leukemic cells. Brochure

THP-1 Reporter Cells

ATCC introduced luciferase reporters containing the response element of immunologically important transcription factors into the THP-1 cell line. The THP-1 LUC2 cell lines provide a means to confidently measure immune modulation for all your drug discovery and development efforts.

CAR-T cells, CAR-Target, CD19, CD20, HER2 Brochure

CAR-T Target Luciferase Reporter Cells

ATCC generated CAR-T Target Luciferase Reporter Cells lines that have high endogenous expression of clinically relevant cell surface tumor antigens, such as CD19, CD20, and HER2. These new immuno-oncology tools are comprised of both solid and liquid tumor cell lines that exhibit sensitive and stable luciferase reporter expression.

Immune checkpoint inhibitors: Interaction between PD-1 (blue) on a T-cell and PD-L1 (red) on a cancer cell blocked by therapeutic antibodies Brochure

Immuno-oncology Capabilities

ATCC provides a large collection of fully characterized and authenticated cell lines, human primary cells, and advanced cell models such as checkpoint luciferase reporter cells and CAR-T target luciferase reporter cells that support immuno-oncology therapeutic development.


Contact us today!

ATCC stands ready to discuss your research needs and provide you with personalized care in sourcing reference materials, managing requests, and providing sales quotes. Please complete our form to let us know how we can help, and we will start working on your needs right away.

We will not share your information outside of our distributors network and solely use it to send relevant communications.
Your form has been successfully submitted